The long term goal of this proposal is to use a molecular genetic approach to investigate the function of nicotinic acetylcholine receptors (nAChR) in the vertebrate central nervous system. Although considerable molecular data regarding the structure and function of nAChR subunits is available, far less is known about neural circuitry or roles subserved by the individual receptors. Moreover, little is known about the physiological consequences of mutations within these genes, the precise roles of receptor subtypes in the normal ontogeny and modulation of central nervous system synapses, or in the establishment of nicotine-induced dependence, tolerance and withdrawal among habitual tobacco users. As a first step towards addressing these issues, this proposal outlines experiments which use homologous recombination to introduce null or altered-function mutations of selected nAChR subunit genes into mice. The rationale for these exploratory studies rests on the assumption that deficits or alterations in targeted genes can, upon analysis of subject animals, reveal or clarify the function of the mutated gene. Specifically, the extant application proposes to utilize recombinant DNA methodologies to construct two strains of mice, the first of which will harbor a deletion of the alpha6 nAChR subunit gene. Since the alpha6 subunit gene is actively transcribed in catecholaminergic nuclei (ventral segmental area, substantia nigra, and locus coeruleus), it is anticipated that null mutants will help to define central nicotinic cholinergic circuits which modulate locomotion. Likewise, an alpha6 null mutation is anticipated to have profound effects on behaviors which originate in the mesolimbic dopamine system and are relevant to the reinforcing properties of nicotine, or to basic motivational processes which underlie learning and cognitive behavior. The second genetically engineered mouse will harbor a specific mutation (Ser248Phe) in the alpha4 nAChR subunit gene. In vitro this mutation potentiates onset and slows recovery from receptor desensitization, while in vivo this mutation is responsible for a human, brain-specific phenotype known as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). The purpose of this part of the proposal is to provide an animal model to analyze the molecular pathology of partial epilepsy, and to offer a paradigm for the development and evaluation of cholinergic therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Research Grants (R03)
Project #
1R03DA011836-01
Application #
2632764
Study Section
Human Development Research Subcommittee (NIDA)
Project Start
1998-04-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Psychiatry
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Whiteaker, Paul; Wilking, Jennifer A; Brown, Robert W B et al. (2009) Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain. Acta Pharmacol Sin 30:795-804
Nakauchi, Sakura; Brennan, Robert J; Boulter, Jim et al. (2007) Nicotine gates long-term potentiation in the hippocampal CA1 region via the activation of alpha2* nicotinic ACh receptors. Eur J Neurosci 25:2666-81
Fonck, Carlos; Nashmi, Raad; Deshpande, Purnima et al. (2003) Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors. J Neurosci 23:2582-90
Labarca, C; Schwarz, J; Deshpande, P et al. (2001) Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci U S A 98:2786-91
Elgoyhen, A B; Vetter, D E; Katz, E et al. (2001) alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci U S A 98:3501-6